Rolf A Brekken Selected Research

Vascular Endothelial Growth Factor Receptors (VEGF Receptors)

6/2013	BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer.
10/2010	Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans.
8/2010	r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction.
7/2009	Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.
11/2008	The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
6/2008	Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice.
1/2007	Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature.
8/2006	Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rolf A Brekken Research Topics

Disease

123	Neoplasms (Cancer) 01/2024 - 10/2002
35	Pancreatic Neoplasms (Pancreatic Cancer) 11/2022 - 10/2004
29	Neoplasm Metastasis (Metastasis) 01/2024 - 09/2003
22	Adenocarcinoma 11/2022 - 03/2005
15	Breast Neoplasms (Breast Cancer) 01/2024 - 09/2006
11	Hypoxia (Hypoxemia) 06/2021 - 09/2003
9	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2023 - 09/2003
8	Lung Neoplasms (Lung Cancer) 01/2017 - 01/2010
5	Carcinogenesis 11/2020 - 08/2010
4	Carcinoma (Carcinomatosis) 11/2022 - 09/2012
4	Melanoma (Melanoma, Malignant) 01/2016 - 12/2011
3	Hepatocellular Carcinoma (Hepatoma) 03/2024 - 12/2016
3	Obesity 01/2021 - 12/2017
3	Fibrosis (Cirrhosis) 11/2020 - 08/2009
3	Stomach Neoplasms (Stomach Cancer) 01/2019 - 04/2015
3	Insulin Resistance 10/2018 - 04/2012
3	Inflammation (Inflammations) 08/2013 - 07/2012
2	Adenocarcinoma of Lung 01/2022 - 10/2013
2	Communicable Diseases (Infectious Diseases) 01/2021 - 01/2021
2	Pancreatitis 11/2020 - 01/2019
2	Type 2 Diabetes Mellitus (MODY) 10/2018 - 09/2010
2	Fatty Liver 10/2018 - 12/2017
2	Weight Loss (Weight Reduction) 10/2018 - 10/2007
2	Thrombosis (Thrombus) 01/2016 - 09/2015
2	Endometrial Neoplasms (Endometrial Cancer) 11/2015 - 07/2010
2	Choroidal Neovascularization 11/2015 - 02/2006
2	Necrosis 01/2011 - 09/2003

Drug/Important Bio-Agent (IBA)

46	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 10/2004
26	Proteins (Proteins, Gene)FDA Link 01/2023 - 03/2005
15	CollagenIBA 01/2021 - 04/2004
13	PhosphatidylserinesIBA 03/2024 - 05/2006
11	Gemcitabine FDA Link 01/2022 - 05/2006
10	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2024 - 10/2015
9	Monoclonal AntibodiesIBA 01/2016 - 09/2003
8	Immune Checkpoint InhibitorsIBA 03/2024 - 01/2016
8	CytokinesIBA 01/2023 - 06/2008
8	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 06/2013 - 08/2006
7	Cysteine (L-Cysteine)FDA Link 01/2023 - 02/2009
7	LigandsIBA 01/2017 - 10/2002
7	IntegrinsIBA 10/2016 - 03/2005
6	Phosphotransferases (Kinase)IBA 01/2019 - 08/2013
5	Discoidin Domain Receptor 1IBA 01/2020 - 01/2017
5	Bevacizumab (Avastin)FDA Link 03/2016 - 05/2009
5	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 10/2014 - 08/2006
4	RNA (Ribonucleic Acid)IBA 01/2022 - 03/2005
4	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2022 - 07/2015
4	c-Mer Tyrosine KinaseIBA 01/2021 - 11/2018
4	Interleukin-6 (Interleukin 6)IBA 11/2019 - 11/2009
4	Estrogens (Estrogen)FDA Link 01/2019 - 09/2006
4	Indicators and Reagents (Reagents)IBA 08/2017 - 10/2013
4	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2016 - 05/2010
4	EnzymesIBA 11/2013 - 08/2006
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2012 - 02/2003
3	bemcentinibIBA 01/2023 - 10/2015
3	pleiotrophin (HARP)IBA 01/2023 - 06/2008
3	AntibodiesIBA 01/2018 - 08/2013
3	Fibrillar CollagensIBA 11/2017 - 08/2009
3	Phospholipids (Phosphatides)FDA LinkGeneric 08/2017 - 01/2016
3	PeptoidsIBA 05/2016 - 07/2010
3	Therapeutic UsesIBA 01/2016 - 05/2006
3	GTP-Binding Proteins (G-Protein)IBA 12/2015 - 07/2010
3	Small Interfering RNA (siRNA)IBA 01/2011 - 07/2005
2	bavituximabIBA 03/2024 - 01/2015
2	Docetaxel (Taxotere)FDA Link 01/2023 - 05/2016
2	AngiopoietinsIBA 01/2022 - 02/2014
2	Transcription Factors (Transcription Factor)IBA 06/2021 - 12/2017
2	CeruletideIBA 11/2020 - 01/2019
2	Axl Receptor Tyrosine KinaseIBA 01/2020 - 09/2015
2	Cadherins (E-Cadherin)IBA 11/2019 - 12/2011
2	tyrosine receptor (receptor, tyrosine)IBA 11/2018 - 08/2013
2	Adenosine Triphosphate (ATP)IBA 11/2017 - 01/2011
2	Biomarkers (Surrogate Marker)IBA 08/2017 - 11/2009
2	Fibronectins (Fibronectin)IBA 10/2016 - 10/2016
2	CarbohydratesIBA 05/2016 - 12/2015
2	Peptides (Polypeptides)IBA 05/2016 - 12/2015
2	LipidsIBA 05/2016 - 12/2015
2	Antineoplastic Agents (Antineoplastics)IBA 12/2015 - 09/2012
2	Warfarin (Coumadin)FDA LinkGeneric 10/2015 - 09/2015
2	CXC ChemokinesIBA 04/2015 - 05/2014
2	nintedanibIBA 03/2015 - 06/2013
2	Neutralizing AntibodiesIBA 05/2014 - 11/2007
2	Cell Surface ReceptorsIBA 02/2014 - 08/2010
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 06/2013 - 11/2012
2	apricoxibIBA 09/2012 - 09/2012
2	matrigelIBA 12/2010 - 10/2007
2	Neuropilin-1IBA 08/2010 - 10/2008
2	Immunoglobulin G (IgG)IBA 07/2009 - 01/2007
2	Extracellular Matrix ProteinsIBA 02/2009 - 03/2005
2	Angiogenesis InhibitorsIBA 10/2007 - 10/2007
2	Progestins (Progestagens)IBA 10/2007 - 09/2006
1	pembrolizumabIBA 03/2024
1	A-Form DNA (A-DNA)IBA 01/2024
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2023
1	Thrombospondin 1IBA 12/2022

Therapy/Procedure

66	Therapeutics 01/2024 - 10/2003
16	Drug Therapy (Chemotherapy) 01/2022 - 05/2006
4	Immunotherapy 01/2022 - 01/2018
4	Aftercare (After-Treatment) 01/2021 - 10/2004
3	Transplantation 11/2020 - 09/2009
2	Blood Transfusion (Blood Transfusions) 08/2010 - 05/2009